Nose and Throat Oropharyngeal Spray

Leveraging our scientific research, FluTrends International is working on a suite of products that are designed to inhibit the Human-to-Human (H2H) transmission for the influenza virus and to treat individuals infected with the flu virus. The first release product, which will be available commercially for the 2011 flu season, has undergone extensive safety testing and is a naturally derived, year-round throat and nose spray designed to effectively prevent the transmission of the flu.

As a throat and nose spray, our product provides enhanced immune system support as well as possible localized protection at the Point of Entry or Point of Transmission by building up the mucous defense systems and providing multiple layered defense protection to combat mutations and improve effectiveness. Specifically the product is designed to work though the following mechanisms:

• Immune system support
• Enhancing the mucous decoy defense system against influenza
• Receptor blockade
• Irreversible Hemagglutinin conformation change
• Puncture and disruption of viral lipid membrane
• Receptor destruction

While the trademark of the influenza virus is its adaptability and mutagenicity, the product has been designed to work against all major classes of the influenza virus. The product uses a “team” approach, where multiple ingredients work together to create the desired effect, a technique that is becoming the norm for treatment of difficult infections. Combination treatment for influenza is very effective and a product that works through this type of approach ensures that it is more difficult to engineer a countermeasure-resistant strain.

An article in the 2011 Journal of Infectious Diseases has shown that the transocular route, involving the nasolacrimal duct and nasopharyngeal cavity, plays a significant role in the transmission of the influenza virus. When ingested, our product is designed to enhance immune system response. Secondarily, it may impede the growth and may in fact disable the influenza virus in the nasopharyngeal cavity.  The combined action should provide effective protection and may give the immune system the response time necessary to coat the influenza virus with antibodies and thus effectively disable the virus.

In regard to retransmission, it is logical that a disabled influenza virus when found in a retransmitted aerosol droplet will not be as infectious.